Backed by almost 15 years of experience providing insights to the antibody-drug conjugate community, World ADC Asia prides itself in being the definitive industry-led conference uniting the leaders and newcomers of the space to identify and discuss the critical factors that will influence the next 12 months of your ADC development.

There has never been a stronger time for antibody drug conjugate drug development in Asia, with the Japanese-born Enhertu reaching blockbuster status; Asia accounting for half of the new ADC clinical trials in 2023 and surpassing the number of those from the US for 5 years in a row.

Across three packed days, with the highest quality industry speakers, you joined the likes of Daiichi Sankyo, Eisai, Shanghai Miracogen, OBI Pharma, Pinotbio, Pfizer, Hummingbird Biosciences, and many others in the APAC region paving the way to innovations. From new approaches to conjugation platforms, tackling challenges within clinical trials of Asian populations, navigating partnering with a CDMO, all with the continued goal of maximizing the therapeutic window of ADCs.

Whether you’re a CEO, Managing Director, head of lab or scientist, this was the meeting for you to get the most up-to-date insight into what’s happening with ADCs in Asia.